Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences in November 2025, highlighting its ongoing commitment to engage with the investment community and showcase its innovative biopharmaceutical pipeline [1][7]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [2][5]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2]. Product Pipeline - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for chronic myelogenous leukemia (CML) patients with specific mutations and is included in the China National Reimbursement Drug List [3]. - Olverembatinib is currently undergoing registrational Phase III trials, including POLARIS-2 for CML and POLARIS-1 and POLARIS-3 for other leukemia types [3]. - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies, with multiple global registrational Phase III trials ongoing [4]. Collaborations and Partnerships - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [5]. - The company collaborates with prominent research institutions such as Dana-Farber Cancer Institute and Mayo Clinic to enhance its research and development capabilities [5].
Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025